GlaxoSmithKline (GSK) Announces Divestiture of non-Core Assets to Aspen

September 12, 2016 7:35 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

GlaxoSmithKline (NYSE: GSK) announces a series of agreements with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.

The agreements announced today are subject to the relevant anti-trust and regulatory clearances.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Mergers and Acquisitions, Spinoffs

Related Entities

Definitive Agreement

Add Your Comment